Summary
Amgen Inc. (AMGN) filed an 8-K on July 29, 2010, to report its unaudited financial results for the second quarter and first half of 2010. The filing primarily focuses on the company's presentation of non-GAAP financial measures, which exclude various items such as stock option expensing, amortization of acquired intangible assets from significant acquisitions (Avidia, Abgenix, Immunex), non-cash interest expense related to convertible notes, and specific legal and restructuring charges. Amgen utilizes these non-GAAP measures to provide supplementary information to investors, aiming to facilitate clearer comparisons of operational performance across different periods by mitigating the impact of non-recurring or accounting-specific adjustments. The company emphasizes that these non-GAAP measures are presented in addition to, and not as a substitute for, GAAP financials. Investors should note the specific nature of the adjustments made to arrive at these figures, including the treatment of acquired intellectual property as if it were internally developed and the exclusion of one-time events like legal settlements and restructuring costs. The filing also mentions the inclusion of adjusted EPS both with and without stock option expensing for comparative convenience.
Key Highlights
- 1Amgen reported its unaudited financial results for the three and six months ended June 30, 2010.
- 2The filing extensively details Amgen's use of non-GAAP financial measures, excluding items like stock option expensing and amortization of acquired intangibles.
- 3Key non-GAAP adjustments include those related to the acquisitions of Avidia, Abgenix, and Immunex.
- 4The company provides non-GAAP measures for cost of sales, R&D expense, SG&A expense, net interest expense, and diluted shares.
- 5Amgen explains its rationale for excluding certain items, such as treating acquired intellectual property as internally developed for profitability comparisons.
- 6The report includes non-GAAP adjusted earnings per share (EPS) both with and without the impact of stock option expensing for investor convenience.
- 7The filing incorporates adjustments for specific events like legal proceedings settlements, restructuring plans, and changes in accounting for convertible notes.